Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Healthpeak Properties Inc V.DOC


Primary Symbol: DOC

Healthpeak Properties, Inc. is a fully integrated real estate investment trust (REIT). The Company acquires, develops, owns, leases, and manages healthcare real estate across the United States. Its strategy is to invest in and manage real estate focused on healthcare discovery and delivery. It has a diversified portfolio of high-quality healthcare properties across three core asset classes of lab, outpatient medical, and continuing care retirement community (CCRC) real estate. The Company’s segments include Lab, Outpatient medical and CCRC. The lab segment properties contain laboratory and office space, are leased primarily to biotechnology, medical device and pharmaceutical companies, scientific research institutions, government agencies, and other organizations involved in the life science industry. The Outpatient Medical segment includes outpatient medical buildings and hospitals. Outpatient medical buildings typically contain physicians’ offices and examination rooms.


NYSE:DOC - Post by User

Comment by Defiance2050on Aug 18, 2022 5:43pm
178 Views
Post# 34906002

RE:Canaccord

RE:Canaccord
retiredcf wrote:

“Our new $0.45 target price (from $1.50) equates to 0.8 times our 2022 estimated EV/Sales and 0.7 times NTM+1 EV/Sales (ending March 2024),” he said. “While this presents a significant discount to peers on an EV/sales basis (WELL trades at 2.5 times 2022 EV/sales for example), we believe a discounted valuation is likely to persist until the company can rightsize its cost base in order to drive towards sustainable margins.”



Haven't personally looked deeply into WELL however, I suspect that their clinc business skews the EV / sales numbers. Definately not a great trend with recent acquisitions. It will be interesting to see if insiders purchase shares after results and how synergys show up in the results in the first full quarter after the Mindbeacon acquisition. 

<< Previous
Bullboard Posts
Next >>